Nerviano Medical Sciences S.r.l.

Pfizer Italia S.r.l.

Alessia Montagnoli

Paolo Orsini

Alessandra Scolaro

Gianluca Mariano Enrico Papeo

Fabio Zuccotto

Barbara Forte

Helena Posteri

Giovanni Cervi

Jay Aaron Bertrand

Rosita Lupi

Mario Varasi

Ermes Vanotti

Dario Ballinari

Antonio Pillan

Enrico Pesenti

Roberto D'Alessio

Marcellino Tibolla

Antonella Ciavolella

Corrado Santocanale

Gianluca Mariano Papeo

The present invention provides a therapeutic combination comprising (a) a compound of formula (I) as set forth in the specification and (b) one or more antineoplastic agents selected from the group consisting of an alkylating or alkylating-like agent, an antimetabolite agent, a topoisomerase I inhibitor, a topoisomerase II inhibitor, an inhibitor of a growth factor or of a growth factor receptor, an antimitotic agent, a proteasome inhibitor, an inhibitor of an anti-apoptotic protein and an antibody directed against a cell surface protein, wherein the active ingredients are present in each case in lice form or in the form of a pharmaceutically acceptable salt or any hydrate thereof.

Therapeutic combination comprising a Cdc7 inhibitor and an anti-neoplastic agent

There are provided substituted isoquinolin-1(2H)-one derivatives which selectively inhibit the activity of poly (ADP-ribose) polymerase PARP-1 with respect to poly (ADP-ribose) polymerase PARP-2. The compounds of the present invention are therefore useful in treating diseases such as cancer, cardiovascular diseases, central nervous system injury and different forms of inflammation. The present invention also provides methods for preparing these compounds, pharmaceutical compositions comprising these compounds, and methods of treating diseases utilizing pharmaceutical compositions comprising these compounds. A screening method for the identification of compounds capable of binding several PARP proteins, as well the probes used in such method, are further objects of the invention.

Isoquinolin-1(2H)-one derivatives as PARP-1 inhibitors

Isoquinolin-1 (2H)-one derivatives as PARP-1 inhibitors

Pyrimidylpyrrole derivatives of formula (I) and pharmaceutically acceptable salts thereof, as defined in the specification, process for their preparation and pharmaceutical compositions comprising them are disclosed; the compounds of the invention may be useful, in therapy, in the treatment of diseases associated with a disregulated protein kinase activity, like cancer.

Pyrimidylpyrrole derivatives active as kinase inhibitors

Growing community of inventors

Milan, Italy

Alessia Montagnoli